Detail akcie Editas Medicine online

Business Summary: Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Editas Medicine Inc revenues increased 79% to $14.7M. Net loss decreased 67% to $43.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects clinical stage gene editing segment loss decrease of 66% to $43.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.54678 to -$0.40804.